Navigation Links
IBA Molecular Introduces Centers for Innovation

DULLES, Va., Sept. 10, 2012 /PRNewswire/ -- IBA Molecular North America, Inc. (IBA Molecular), a leading manufacturer and distributor of PET imaging tracers, has announced the introduction of its Centers for Innovation, two unique facilities designed for advanced radiopharmaceutical contract development and manufacturing. The centers are located in Totowa and Somerset, New Jersey.  Complementing these sites are IBA Molecular's production capabilities for isotopes such as I-124, F-18, Zr-89 and, in the future, Cu-64 and Y-86. The centers are expected to play an important role in the development of a new generation of disease-specific tracers and companion theragnostics.

The primary site is a state-of-the-art radiopharmaceutical facility in Totowa, New Jersey. This fully equipped 8500 sq. ft. research and development center is staffed by a team of accomplished professionals, including radiochemists, nuclear pharmacists, QC chemists and cyclotron engineers with well over a century of combined professional experience. The staff has expertise in radio-labeling, product development and industrialization of new tracers, technology transfer and GMP production of doses for clinical trials.  These attributes make the site an ideal destination for collaborative projects. With both large (mAbs, proteins etc.) and small molecule radio-labeling expertise, the center can develop processes to support almost any new tracer including those that utilize isotopes such as F-18, I-124 and Zr-89.  All of these endeavors are geared towards supporting human clinical trials of novel tracers.   

These GMP-validated sites provide a broad range of capabilities, including:

  • Compounding of I-124 capsules for clinical use
  • Producing the highest purity I-124 available under a DMF for this radioisotope
  • Production of novel tracers integral to pre-clinical translational research
  • Scalable infrastructure and investigational products for all phases of clinical studies
  • Production of novel tracers integral to hybrid-probe development
  • A supporting resource or "think-tank" for development and industrialization
  • Scalable infrastructure capable of supporting solid targetry for research isotope production including Cu-64, Y-86 and other isotopes

"The molecular imaging industry needs an accelerant to drive innovation and new products. Our specialized knowledge and outstanding facilities in radiopharmaceutical development and manufacturing are at the disposal of our partners and will undoubtedly assist in bringing new products to the market faster," said Lee Karras, president of IBA Molecular North America, Inc. He further stated, "These Centers for Innovation will provide researchers, pharma and biotech companies with access to our unmatched expertise in small and large molecules as well as our proven track record with the development of novel tracers.  Standing alongside these centers is IBA Molecular's global commercial network of nuclear pharmacies, which will be paramount to the successful launch of any new, commercialized tracer."

IBA Molecular has development and manufacturing partnerships with a number of pharmaceutical firms, including WILEX, Aposense and Piramal Imaging, as well as ongoing research collaborations with noted medical institutions throughout the U.S. and Europe.

About IBA Molecular North America, Inc.

IBA Molecular North America, Inc. is part of IBA Molecular, a global developer, manufacturer and distributor of radiopharmaceutical products and supporting services used in molecular imaging. IBA Molecular has engineered a strong and unique product portfolio and pipeline of diagnostic and therapeutic tracers aimed at advancing the development of the global movement towards personalized medicine and making molecular imaging/therapy a major discipline in healthcare. The company also provides educational, technical and marketing support to medical specialists worldwide to help better respond to patient needs.

Please visit for more information about IBA Molecular.

SOURCE IBA Molecular
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress
2. Quest Diagnostics Launches Molecular Cervical Cancer Test Based on National Institutes of Healths TERC Gene Marker
3. Agendia Brings Together Thought Leaders in Molecular Diagnostics and Medical Oncology
4. New Molecular Assay Allows Healthcare Facilities to Simplify Active Surveillance Testing for Deadly Superbug
5. IBA Molecular, Piramal Imaging Sign Agreement for New F-18 Amyloid Imaging Agent
6. Science Translational Medicine and the DMM Global Foundation Announce Days of Molecular Medicine 2012 "The Translational Science of Rare Diseases: From Rare To Care."
7. Amsterdam Molecular Therapeutics (AMT) Holding N.V. (in liquidation) Announces Publication of its Accounts for 2011 and Notice of Annual General Meeting
8. BSGI Molecular Breast Imaging Proves Equivalent to MRI in Breast Cancer Patient Management
9. BSGI Molecular Breast Imaging Provides Better Results than MRI for Cancer Patients with Dense Breasts
10. The 2012 US Molecular Diagnostics Market
11. QIAGEN Unveils Initiative to Create Next-Generation Sequencing Portfolio for use in Clinical Research and Molecular Diagnostics
Post Your Comments:
(Date:11/25/2015)...  Linden Care, LLC, a retail specialty pharmacy focused ... suffering from chronic pain, said today that it is ... (TRO) enjoining Express Scripts from unilaterally terminating the Pharmacy ... --> --> The company said that ... --> --> In ...
(Date:11/25/2015)... USA , Inc., a leader in ... accuracy of its blood glucose meter systems. Last week ... Cardiovascular Disease in Los Angeles , ... 01 meter and the Assure ® Prism multi-user ... measure glucose levels in blood is essential for people ...
(Date:11/25/2015)... , Nov. 25, 2015 Allergan plc (NYSE: ... agreement with the New York State ... of the Sherman Act, and other statutes with the Attorney ... February 2014, to cease marketing and selling the now generic ... settlement, Allergan admits no liability, has released its counterclaims against ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... 26, 2015 , ... PRMA Plastic Surgery is updating their record books yet ... 6,000th free flap breast reconstruction surgery! , “What an accomplishment for the PRMA team, ... lives and it’s an honor to have served all of these women.” , PRMA ...
(Date:11/26/2015)... Viejo, CA (PRWEB) , ... November 26, 2015 ... ... users a new set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This ... style options. These classically-influenced trailer titles work with any font, giving users limitless ...
(Date:11/26/2015)... ... ... Inc., developer and distributor of the world-class Asterisk based contact center software Q-Suite, announces ... new Q-Suite 6 platform is based on the latest Java Enterprise standards. By conforming ... of software for many key components of the suite. Much of the suite runs ...
(Date:11/25/2015)... ... November 25, 2015 , ... As part of a ... ™ attracts volunteers together who want to combine talents and resources to help ... in the process. The non-profit launched its first major fundraiser on November 6, ...
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in the traditional and far-infrared ... traditional and far-infrared saunas. , For traditional saunas, Finnleo is offering ... sauna wood, and Finnleo uses only European Grade A Nordic White Spruce from sustainably ...
Breaking Medicine News(10 mins):